You are here

Investor Relations


Message from our CEO

812x408 Jeffrey Leiden_0.png

Jeffrey Leiden, Chairman, President and CEO

Latest Press Releases

Date Title and Summary
Toggle Summary Vertex to Announce Third Quarter 2018 Financial Results on October 24
BOSTON --(BUSINESS WIRE)--Oct. 16, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
Toggle Summary CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
ZUG, Switzerland   and   BOSTON   and   CAMBRIDGE, Mass. ,   Oct. 10, 2018   (GLOBE NEWSWIRE) --   CRISPR Therapeutics  (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and   Vertex Pharmaceuticals Incorporated   (NASDAQ:VRTX)
Toggle Summary Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines
- First-of-its-kind contract with the Danish pharmaceutical and procurement organization, Amgros, is effective from today - - Vertex also announces reimbursement in Austria for ORKAMBI ® (lumacaftor/ivacaftor) to treat patients ages 6 through 11 with two copies of the F508del mutation - LONDON

Copyright West LLC. Minimum 15 minutes delayed.